Evidence map›Paper›PMID 37184670›Full record

ArticlemSystems2023

Milka Marjut Hammarén, Hanna Luukinen, Alina Sillanpää, Kim Remans, Karine Lapouge, Tânia Custódio, Christian Löw, Henna Myllymäki, Toni Montonen, Markus Seeger and 4 more

Open access · goldAbstract read
In one paragraph

Article in mSystems, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.6field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Biofilm Associated Persistence and Drug Tolerance in Mycobacteria Within Host Microenvironments.APMIS : acta pathologica, microbiologica, et immunologica Scandinavica · 2026
    Review
  3. Journal of bacteriology · 2025
    Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 6 institutions in 4 countries.

Milka Marjut Hammarén *Faculty of Medicine and Health Technology, Tampere University , Tampere, Finland.ORCID 0000-0001-9076-8782
Hanna Luukinen *Faculty of Medicine and Health Technology, Tampere University , Tampere, Finland.ORCID 0000-0002-9334-6304
Alina SillanpääFaculty of Medicine and Health Technology, Tampere University , Tampere, Finland.ORCID 0000-0003-4554-6595
Kim RemansEuropean Molecular Biology Laboratory , Heidelberg, Germany.ORCID 0000-0002-4394-7953
Karine LapougeEuropean Molecular Biology Laboratory , Heidelberg, Germany.ORCID 0000-0003-0620-9553
Tânia CustódioCentre for Structural Systems Biology , Hamburg, Germany.ORCID 0000-0002-5723-9093
Christian LöwCentre for Structural Systems Biology , Hamburg, Germany.ORCID 0000-0003-0764-7483
Henna MyllymäkiFaculty of Medicine and Health Technology, Tampere University , Tampere, Finland.ORCID 0000-0002-6936-4879
Toni MontonenFaculty of Medicine and Health Technology, Tampere University , Tampere, Finland.ORCID 0000-0003-3784-0890
Markus SeegerInstitute for Medical Microbiology, University of Zurich , Zurich, Switzerland.ORCID 0000-0003-1761-8571
Joseph RobertsonDepartment of Immunology, University of Oslo , Oslo, Norway.
Tuula A NymanDepartment of Immunology, University of Oslo , Oslo, Norway.ORCID 0000-0001-8787-5886
Kirsi Savijoki *Faculty of Medicine and Health Technology, Tampere University , Tampere, Finland.ORCID 0000-0001-5325-925X
Mataleena Parikka *Faculty of Medicine and Health Technology, Tampere University , Tampere, Finland.ORCID 0000-0001-5555-3815
Tampere University · FIDeutsches Elektronen-Synchrotron DESY · DEEuropean Molecular Biology Laboratory · DEOslo University Hospital · NOUniversity of Helsinki · FIUniversity of Zurich · CH

Funding

Academy of Finland (AKA) 326674, 322010, 326584, 348968Academy of Finland (AKA) 338624Biocenter Finland (BF)Core Facilities programme of the South-Eastern Norway Regional Health AuthorityJane and Aatos Erkko FoundationResearch Council of Norway INFRASTRUKTUR-programme 295910Sigrid Juséliuksen Säätiö (Sigrid Jusélius Stiftelse)Tampereen Tuberkuloosisäätiö (Tampere Tuberculosis Foundation)
6 · The paper itself

Abstract

The antibiotic-tolerant biofilms present in tuberculous granulomas add an additional layer of complexity when treating mycobacterial infections, including tuberculosis (TB). For a more efficient treatment of TB, the biofilm forms of mycobacteria warrant specific attention. Here, we used

Indexed as

Mycobacterium marinumSingle-Domain AntibodiesTuberculosisAnimalsAnti-Bacterial AgentsBiofilmsProteomicsZebrafishAnti-Bacterial AgentsSingle-Domain Antibodiesbiofilmbiofilm-targeted therapyMycobacteriumnanobodysurface proteomesynthetic nanobody libraries

Identifiers

PMID37184670
PMCPMC10308901
OpenAlexW4376630639

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.